Among HomoMut patients, the median PFS was 9.1 months for those receiving the full dose and 15.2 months for those requiring dose reduction; however, this difference did not reach statistical significance ( p = 0.782).
← all excerpts
Impact of <i>UGT1A1*28</i> Allele on the Safety and Effectiveness of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: Real-World Evidence.
2
0.7820
0.7820
The sentences
The rate of grade ≥ 2 febrile neutropenia was higher among HomoMut patients and, although no statistically significant differences were observed in the other AEs analyzed, there was a clear trend toward a greater toxicity in the HomoMut group, particularly in terms of grade ≥ 2 diarrhea and anemia.